GlassScriptPhysician profile
Mallory C Whitley
NPI 1861913592
$6,208.82
in general payments reported to CMS, 2019-2025
43 companies · $93.80 in 2025
The $93.80 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $636 · 2021: $1,590 · 2022: $1,693 · 2023: $1,785 · 2024: $412 · 2025: $93.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,229 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,229.19 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $840.46 | 2020-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $676.63 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $388.33 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $370.21 | 2020-2024 | Lokelma, Airsupra, Breztri |
| Amarin Pharma, INC. | $356.03 | 2020-2022 | |
| Abbvie INC. | $334.50 | 2021-2024 | Qulipta |
| Astellas Pharma US INC | $329.79 | 2020-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $319.88 | 2021-2024 | |
| Lilly USA, LLC | $262.60 | 2022-2024 | Mounjaro, Jardiance, Baqsimi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.10 | 2021-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $198.73 | 2020-2023 | Trintellix |
| Eisai INC. | $168.75 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $134.97 | 2022-2024 | Quviviq |
| Sun Pharmaceutical Industries INC. | $119.05 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $111.38 | 2021-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Whitley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.